Jennifer N Clements

Considerations and challenges in microdosing of GLP-1-based receptor agonists.

Expert Opinion on Pharmacotherapy September 25, 2026 Haley Beck, Jennifer N Clements

This commentary summarizes the pharmacologic rationale, emerging evidence, clinical considerations, and limitations of microdosing glucagon-like peptide-1 (GLP-1)-based therapies. Microdosing of single or dual GLP-1 receptor agonists (RAs) has emerged as an off-label strategy to improve tolerability, reduce cost, and expand access during periods of medication shortages. Although standard doses...